Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy

Kanat, Özkan; Ertas, Hulya

doi:10.5306/wjco.v10.i2.52

Cited by 18 publications

(15 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ramucirumab, an antiangiogenic agent, is a human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2 . Several phase III studies have shown that the addition of ramucirumab to a chemotherapy regimen improves the overall survival of patients with gastric cancer, gastroesophageal junction adenocarcinoma, and colorectal cancers .…”

Section: Discussionmentioning

confidence: 99%

Severe esophageal stenosis in a patient with metastatic colon cancer following palliative radiotherapy, ramucirumab, and chemotherapy

Akahane

Shirai

Wakatsuki

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Severe esophageal stenosis in a patient with metastatic colon cancer following palliative radiotherapy, ramucirumab, and chemotherapy

Akahane

Shirai

Wakatsuki

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…This causes a conformational change that prevents the binding of the VEGFR ligands VEGF‐A, VEGF‐C, and VEGF‐D. These ligands are secreted by solid tumors to promote angiogenesis 51 . Ramucirumab was approved by the FDA in 2015 to treat metastatic CRC in patients that had experienced disease progression on or after prior therapy with bevacizumab, oxaliplatin, and 5‐FU/capecitabine.…”

Section: Targeted Therapeuticsmentioning

confidence: 99%

Pharmacogenomic‐Guided Therapy in Colorectal Cancer

Diasio

Innocenti

Offer

2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Approximately 20 drugs have been shown to be effective for the treatment of colorectal cancer (CRC). These drugs are from several classes of agents and include cytotoxic drugs, therapeutics that target cell signaling pathways at the extracellular and/or intracellular levels, and combination therapies that contain multiple targeted agents and/or cytotoxic compounds. Targeted therapeutics can include monoclonal antibodies, fusion proteins, and small molecule drugs. The first introduced into clinical use was 5‐fluorouracil in the early 1960s and remains the foundation for most CRC treatments in both adjuvant therapy and in advanced (metastatic) treatment regimens. As with other cancers, the consideration of biomarkers has the potential to improve CRC therapy through patient stratification. The biomarkers can include germline genetic markers, tumor‐specific genetic markers, immune markers, and other biomarkers that can predict antitumor efficacy or the likelihood of toxicity prior to administration of a specific drug. Consistent with the benefit of considering biomarkers in treatment, many newer targeted therapies are developed and approved simultaneously with a companion diagnostic test to determine efficacy. This review will focus on biomarkers that have demonstrated clinical utility in CRC treatment; however, it is noted that many additional biomarkers have been theorized to contribute to drug response and/or toxicity based on known biological pathways but thus far have not attained widespread use in the clinic. The importance of pretreatment biomarker testing is expected to increase as future drug development will likely continue to focus on the concurrent development of companion diagnostics.

show abstract

“…For anti-cancer activity xenograft model, a total of 24 six-week-old nude mice (National Laboratory Animal Center (NLAC), Taipei, Taiwan) were injected subcutaneously with the same volume of Matrigel (BD bioscience, San Jose, California, USA), and 1×10 7 of HCT-116 cells into the right ank of each animal. When tumors had grown to around 300 mm 3 , the treatment started. Tumor size was measured twice weekly and calculated from V = length* width 2 /2.…”

Section: In Vivo Animal Modelsmentioning

confidence: 99%

EGFL6 Promotes Colorectal Cancer Cell Growth and Mobility and the Anti-cancer Property of Anti-EGFL6 Antibody

Sung

Huang

Cheng

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundA reliable cancer biomarker will be critical for advanced colorectal cancer (CRC) therapeutic approaches since current treatments are limited to certain patient characteristics, such as age, sex, comorbidities and patients received self-expandable metal stents implantations. The association of epidermal growth factor-like domain 6 (EGFL6) with cancer development has been reported. Here, we focused on the role of EGFL6 in CRC progression and its clinical relevance. MethodsAn anti-EGFL6 antibody was generated by phage display technology to investigate the potential therapeutic efficacy in CRC. Methylene blue staining was applied to investigate the EGFL6 expression in CRC patients and animal tissue. Protein and DNA level of EGFL6 expression as well as related pathway investigation were determined by western blot and quantitative real time PCR. Silence EGFL6 by siRNA transfection, transwell migration and invasion assay were performed to verify EGFL6 function. Student t test, Kruskal-Wallis test and multiple comparisons were used to statistical analysis results. ResultsSignificant EGFL6 expression was found in colon tissues from patients and spontaneous tumorigenesis mouse but not in normal tissue. Furthermore, we found EGFL6 could enhance cancer cell migration, invasion and proliferation in CRC via up-regulating ERK/ AKT pathway, as well as reducing ADAMTS1 and Snail expression. We also found EGFL6 regulates cell abilities through EGFR/αvβ3 integrin receptors. By conducting animal experiments, our anti-EGFL6 antibody, EGFL6-E5-IgG, showed tumor inhibition and anti-metastasis ability. Furthermore, no impact on angiogenesis and wound healing by using EGFL6-E5-IgG were observed. ConclusionsWe demonstrated that EGFL6 plays a role in CRC tumorigenesis and tumor progression, indicating that EGFL6 is a potential cancer biomarker and therapeutic target worth further investigation.

show abstract

Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy

Cited by 18 publications

References 43 publications

Severe esophageal stenosis in a patient with metastatic colon cancer following palliative radiotherapy, ramucirumab, and chemotherapy

Severe esophageal stenosis in a patient with metastatic colon cancer following palliative radiotherapy, ramucirumab, and chemotherapy

Pharmacogenomic‐Guided Therapy in Colorectal Cancer

EGFL6 Promotes Colorectal Cancer Cell Growth and Mobility and the Anti-cancer Property of Anti-EGFL6 Antibody

Contact Info

Product

Resources

About